

MEDIA CONTACTS

Heather Cox
FierceMarkets, Inc.
202-628-8778 x13
heather@fiercemarkets.com

For Syndax:
Carole Melis
650-342-5686
cmelis@aol.com

FierceBiotech Names Syndax Pharmaceuticals as One of the "Fierce 15" Biotech Companies of 2007

Syndax Pharmaceuticals is "Fierce," on Leading Edge of Biotech

Waltham, MA – June 6, 2007 – Syndax Pharmaceuticals, Inc. announced today that it has been named to the annual FierceBiotech "Fierce 15" list, designating it as one of the top biotech companies of 2007. The editors of FierceBiotech evaluated hundreds of privately-held firms based on company vision, revenue potential, quality of deals, strength of technology, partnerships, and competitive market position. Syndax Pharmaceuticals was determined to be one of the "fiercest," proven by their creativity and innovations in the industry.

An internationally recognized daily newsletter reaching more than 56,000 biotech and pharma industry professionals, FierceBiotech provides subscribers with a quick authoritative briefing on the day's top stories, with a special focus on drug discovery and clinical trials.

"With cash and a keen understanding of the virtual model for biotech start-ups, Syndax is helping demonstrate how a fledgling company can swiftly vault ahead," said John Carroll, editor of FierceBiotech.

Formed in 2005, Syndax is an oncology-focused biopharmaceutical company with a lead product, SNDX-275, expected to enter Phase 2 clinical trials in certain hematological and solid tumor indications later this year. In April 2007, Syndax closed a \$40 million Series A financing co-led by Domain Associates and MPM Capital, with participation from Avalon Ventures, Forward Ventures, and Pappas Ventures.

"Being selected as a member of the 'Fierce 15' is an honor that highlights Syndax Pharmaceuticals' potential to make a significant impact in the biotech market," said Joanna Horobin, M.D., Syndax president and chief executive officer. "SNDX-275 is a selective histone deacetylase inhibitor (HDACi) that has already demonstrated safety, tolerability and clinical activity in clinical testing in more than 200 patients. Our recent in-licensing of this compound catapults Syndax forward as an oncology drug development company."

The Fierce 15 celebrates the spirit of being “fierce” – championing innovation and creativity, even in the face of intense competition. The complete list of ‘Fierce 15’ companies is available in today’s issue of FierceBiotech and on the FierceBiotech Web site at www.fiercebiotech.com.

About FierceMarkets

FierceMarkets is a digital business media company serving vertical markets with email newsletters, web sites, and live events. Based in Washington, DC, FierceMarkets publications reach more than 450,000 executives in over 100 countries every business day. Current publications include DailyTechRag (<http://www.dailytechrag.com>), FierceBioResearcher (<http://www.fiercebioresearcher.com>), FierceBiotech (<http://www.fiercebiotech.com>), FierceBioResearcher (<http://www.fiercebioresearcher.com>), FierceCIO (<http://www.fiercecio.com>), FierceDeveloper (<http://www.fiercedeveloper.com>), FierceFinance (<http://www.fiercefinance.com>), FierceGameBiz (<http://www.fiercegamebiz.com>), FierceHealthcare (<http://www.fiercehealthcare.com>), FierceHealthIT (<http://www.fiercehealthit.com>), FierceIPTV (<http://www.fierceiptv.com>), FierceMobileContent (<http://www.fiercemobilecontent.com>), FierceSarbox (<http://www.fiercesarbox.com>), FierceVoIP (<http://www.fiercevoip.com>), FierceWiFi (<http://www.fiercewifi.com>), FierceWireless (<http://www.fiercewireless.com>), and IT-Wireless (<http://www.it-wireless.com>), and The Business VoIP Report (<http://www.businessvoipreport.com>).

About Syndax

Syndax Pharmaceuticals, Inc. is a Waltham, MA-based, oncology-focused biopharmaceutical company with a lead product candidate, SNDX-275, expected to enter Phase 2 clinical trials in 2007. Syndax is building a portfolio of new oncology products to extend and improve the lives of patients by developing and commercializing novel cancer therapies in optimized, mechanistically driven combination regimens. Formed in 2005, the company's intellectual property is based on work from scientific founder Ronald Evans, PhD, recipient of the 2004 Albert Lasker Prize for Basic Medical Research, a Member of the National Academy of Sciences, a professor at the Salk Institute for Biological Studies and a Howard Hughes Medical Institute Investigator.

###